Regencell Bioscience (NASDAQ:RGC) Reaches New 52-Week Low – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC) hit a new 52-week low during mid-day trading on Wednesday . The company traded as low as $5.80 and last traded at $6.09, with a volume of 445073 shares trading hands. The stock had previously closed at $6.19.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The stock has a 50 day simple moving average of $22.20 and a 200-day simple moving average of $25.46.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported ($0.00) EPS for the quarter.

Institutional Trading of Regencell Bioscience

Institutional investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP bought a new stake in Regencell Bioscience during the 4th quarter valued at about $92,000. Amundi purchased a new stake in shares of Regencell Bioscience during the first quarter valued at approximately $219,000. Vident Advisory LLC grew its holdings in shares of Regencell Bioscience by 65.7% during the fourth quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock valued at $629,000 after buying an additional 11,866 shares during the last quarter. Hudson Bay Capital Management LP bought a new stake in shares of Regencell Bioscience during the fourth quarter valued at approximately $275,000. Finally, Bank of America Corp DE increased its position in shares of Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares in the last quarter. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.